QIAGEN Collaboration and Co-Marketing Agreement

AI SummaryClose X

Cellbxhealth plc has announced a non-exclusive Collaboration and Co-Marketing Agreement with QIAGEN Manchester Ltd. to advance circulating tumour cell (CTC) research with pharmaceutical partners. This agreement allows QIAGEN to offer Cellbxhealth's Parsortix platform alongside its molecular technologies for drug development, biomarker discovery, and companion diagnostic feasibility studies. QIAGEN may contract directly with pharmaceutical partners, outsourcing exploratory CTC projects to Cellbxhealth, which will integrate the Parsortix platform with QIAGEN's PCR, digital PCR, and NGS workflows to provide deeper insights into tumour biology and therapeutic response, potentially leading to the development of a companion diagnostic assay.

Disclaimer*

UK 100

Latest directors dealings